Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

KEYNOTE-183 Investigators

    Research output: Contribution to journal › Article › peer-review

    178 Scopus citations

    Fingerprint

    Dive into the research topics of 'Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial'. Together they form a unique fingerprint.

    Medicine & Life Sciences